Cogent Biosciences (NASDAQ:COGT) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Cogent Biosciences (NASDAQ:COGTFree Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $19.00 price target on the technology company’s stock.

COGT has been the topic of several other reports. Needham & Company LLC restated a buy rating and issued a $18.00 price objective on shares of Cogent Biosciences in a research report on Wednesday, May 8th. JPMorgan Chase & Co. upped their price objective on Cogent Biosciences from $18.00 to $20.00 and gave the company an overweight rating in a research report on Tuesday, February 27th. Wedbush restated a neutral rating and issued a $10.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 24th. Robert W. Baird restated a neutral rating and issued a $8.00 price objective (down from $14.00) on shares of Cogent Biosciences in a research report on Monday, February 26th. Finally, Citigroup upped their price objective on Cogent Biosciences from $11.00 to $13.00 and gave the company a buy rating in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $14.67.

Check Out Our Latest Analysis on Cogent Biosciences

Cogent Biosciences Stock Performance

Cogent Biosciences stock opened at $8.36 on Monday. The firm has a market capitalization of $799.30 million, a price-to-earnings ratio of -3.37 and a beta of 1.60. Cogent Biosciences has a fifty-two week low of $3.67 and a fifty-two week high of $13.36. The stock’s fifty day moving average is $7.62 and its two-hundred day moving average is $6.71.

Cogent Biosciences (NASDAQ:COGTGet Free Report) last posted its earnings results on Tuesday, May 7th. The technology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, sell-side analysts forecast that Cogent Biosciences will post -2.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Cogent Biosciences

Several large investors have recently added to or reduced their stakes in the business. AJOVista LLC acquired a new stake in Cogent Biosciences during the fourth quarter worth about $45,000. China Universal Asset Management Co. Ltd. increased its stake in Cogent Biosciences by 355.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,961 shares of the technology company’s stock worth $59,000 after acquiring an additional 7,772 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Cogent Biosciences by 234.5% during the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock worth $67,000 after acquiring an additional 7,020 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Cogent Biosciences during the fourth quarter worth about $70,000. Finally, NEOS Investment Management LLC acquired a new stake in Cogent Biosciences during the fourth quarter worth about $76,000.

Cogent Biosciences Company Profile

(Get Free Report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

See Also

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.